Cancer Archives

Sitryx immunometabolism cancer inflammation

News and Trends 8 Oct 2018

Oxford Biotech Launches with €26M to Target ‘Immunometabolism’

Sitryx has launched today with the goal of treating cancer and inflammatory conditions by targeting the metabolism of immune cells, a promising area of research. The new company has kicked off with a €26M Series A round co-led by two specialized investors, SV Health and Sofinnova Partners. Sitryx also has investment from GSK, with […]

October 8, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 1 Oct 2018

Cancer-Sniffing Diagnostics Company Secures €43.1M Funding

Intoxication is not the only condition that we could diagnose with breathalyzers. The UK-US company Owlstone Medical has secured €43.1M funding to help commercialize its tech that ‘smells’ cancer in your breath. Owlstone’s breathalyzer kit diagnoses conditions by measuring volatile organic compounds in a person’s breath. Disease pathologies affect the types and amounts of these […]

October 1, 2018 - 2 minutesmins - By Jonathan Smith

News and Trends 20 Sep 2018

RNA Therapy Shows Promise for Treating Liver Cancer

British biotech MiNA Therapeutics’ innovative RNA treatment may enhance liver cancer patients’ response to standard cancer therapies, suggest early results from a Phase I/IIa clinical trial. When they received the biotech’s small activating RNA (saRNA) treatment, two patients showed complete responses after being given the cancer treatment sorafenib and one showed a partial response to […]

September 20, 2018 - 2 minutesmins - By Jonathan Smith

Boehringer Ingelheim ViraTherapeutics oncolytic virus

More News! 13 Sep 2018

Boehringer Ingelheim Acquires Oncolytic Virus Biotech Company

Boehringer Ingelheim is paying €210M to acquire all the remaining shares of ViraTherapeutics, an Austrian biotech company developing oncolytic viral therapies for cancer. ViraTherapeutics develops cancer therapies based on viruses that selectively kill tumor cells, based on the principle that cancer cells show defective mechanisms to defend themselves against viruses that are not able to […]

September 13, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 28 Aug 2018

Update: Gilead and Novartis’s CAR T-Cell Therapies Approved in Europe

Update: Following on from earlier approvals in the US, the European Commission announced it has given marketing approval for both Gilead’s Yescarta and Novartis’s Kymriah for treatment of patients with various forms of blood cancer. Yescarta (axicabtagene ciloleucel) can be used to treat adults with a relapsed or refractory form of the blood cancer diffuse large […]

August 28, 2018 - 4 minutesmins - By Editorial Team

News and Trends 10 Aug 2018

UK Biotech Raises €73M to Target DNA Repair in Treating Cancer

Artios Pharma completed a €73M (£65M) Series B financing round to develop cancer treatments that target DNA repair mechanisms. Cancer occurs when cells in part of the body start dividing uncontrollably as a result of damaged or mutated DNA. In collaboration with Cancer Research UK, Artios Pharma is developing cancer treatments that inhibit proteins involved […]

August 10, 2018 - 3 minutesmins - By Alexander Burik

News and Trends 26 Jul 2018

Replimune’s €85M IPO set to Boost Oncolytic Immunotherapy Pipeline

The US-UK biotech completed its $100M (€85M) IPO on the NASDAQ stock exchange to further develop ‘oncolytic’ immunotherapies that use the herpes virus to target and attack tumor tissue. Replimune’s immunotherapies use the virus to deliver proteins into tumor tissue that help it fuse with the tumor cells. When the virus fuses to tumor cells, it activates […]

July 26, 2018 - 2 minutesmins - By Alexander Burik

News and Trends 25 Jul 2018

Austrian Researchers Grow Cancerous Mini Brains in a Dish

Researchers in Vienna are growing mini brains that mimic the onset and development of brain cancer, which could be used to compare the efficacy of different treatments. Because of their cellular complexity, brain cancers have been difficult to study in animals. Glioblastoma, the most aggressive form of brain cancer, is particularly difficult to treat because […]

July 25, 2018 - 2 minutesmins - By Alexander Burik

Interview 24 Jul 2018

Meet the Dutch Scientists who Invented Keytruda, “The President’s Drug”

Known for curing US President Jimmy Carter’s cancer, Keytruda continues to benefit many other cancer patients. The inventors told us their story, from the drug’s early days to their current role as executives of the biotech unicorn Aduro. Since 2014, the cancer drug Keytruda, also known as pembrolizumab, continues to be widely sought after due […]

July 24, 2018 - 6 minutesmins - By Editorial Team

News and Trends 12 Jul 2018

Collaboration Worth Over €1Bn Could Give Rise to New Cancer Immunotherapies

Genmab is partnering with the German company Immatics to develop immunotherapies directed against three cancer targets. Genmab has offered Immatics, based in Tuebingen, Germany, an upfront payment of $54M (€46M) in addition to milestone payments worth up to $550M (€470M) for each product. Genmab has a market cap of €60Bn ($70Bn). The funding will be […]

July 12, 2018 - 2 minutesmins - By Alexander Burik

News and Trends 11 Jul 2018

Radioactive Nanoparticle Could Improve Cancer Diagnoses

Isotopia Molecular Imaging, an Israeli company, is developing a radioactive marker made of gold nanoparticles to detect cancer more accurately than with current diagnostic tools. PET and CT scans are two types of X-ray tests that use small quantities of radioactive materials, called contrast agents, to help visualize and assess organ and tissue function. These […]

July 11, 2018 - 2 minutesmins - By Alexander Burik

News and Trends 29 Jun 2018

Update: Yet Another ADC Company Makes Bank, This Time in Series B

Update (29.06.2018): NBE Therapeutics has extended its Series B fundraising round by 20M CHF (€17.3M), reaching a total of 40M CHF (€34.6M) for the round. Novo Holdings joins the Boehringer Ingelheim Venture Fund and the PPF Capital Partners Fund as a major shareholder of the Swiss biotech, which continues to develop its ADCs for improved […]

June 29, 2018 - 3 minutesmins - By Editorial Team

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us